



M I C R O L O G I X

| NEWS RELEASE |

Micrologix Biotech Inc. | BC Research Complex | 3650 Wesbrook Mall | Vancouver BC Canada V6S 2L2

FOR IMMEDIATE RELEASE

Micrologix to Present at UBS Global Life Sciences Conference

Vancouver, BC, CANADA – September 18, 2003 – Micrologix Biotech Inc. (**TSX: MBI; OTC: MGIXF**), a developer of anti-infective drugs, will present at the UBS Global Life Sciences Conference in New York, NY on September 25, 2003. James DeMesa, M.D., President and CEO, will present the Company's strategy, pipeline, and progress in the Baroque Room at the Plaza Hotel in New York at 4:30PM EDT on Thursday, September 25, 2003.

Dr. DeMesa will also present at two other fall healthcare conferences: the 8th Annual Orion Healthcare Conference in Toronto at 3:00 PM EDT on September 24, 2003 at the Sheraton Centre Hotel and BioContact 2003 in Quebec City at 2:30PM EDT on October 1, 2003 at the Chateau Frontenac.

Investors may access a live audio web cast of the UBS presentation at <http://www.ibb.ubs.com>. We recommend logging on 15 minutes early in order to register and download any necessary software. Replays will be available for 30 days after the presentation at the same web address or by visiting the Micrologix web site, at www.mbiotech.com.

About Micrologix

Micrologix Biotech Inc. is engaged in the research, development, and commercialization of drugs that advance therapy, improve health, and enrich lives. The Company's focus is anti-infective drug development with three product candidates in human clinical development, multiple product opportunities in preclinical development, and several early-stage technologies in various stages of research and evaluation.

Contacts:

Jonathan Burke
Investor & Media Relations
Micrologix Biotech Inc.
Telephone: 604-221-9666 Ext 241
Toll Free: 1-800-665-1968
Email: jburke@mbiotech.com

Shayne Payne/ Dian Griesel, Ph.D
The Investor Relations Group
Telephone: 212-825-3210
Email: theproteam@aol.com

The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.